Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Phase 1 Evaluation Of Ly2606368& A Molecularly Targeted Chk1/2 Inhibitor Therapy& In Combination With Cyclophosphamide Or Gemcitabine For Children And Adolescents With Refractory Or Recurrent Group 3/Group 4 Or Shh Medulloblastoma Brain Tumors
Protocol ID
SJ ELiOT
Disease (Sub Disease)
Brain and Spinal Tumours (Medulloblastoma/ PNET)
Diagnosis Stage
Relapse/ refractory
Location
NSW, QLD, VIC, WA
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
St. Jude Children's Research Hospital
Collaborators
Eli Lilly and Company
Trial Status
Open
Sites
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 1
Age Eligibility
1 year to 25 years
International registry ID's
NCT04023669
Back to Registry
Study Title Phase 1 Evaluation Of Ly2606368& A Molecularly Targeted Chk1/2 Inhibitor Therapy& In Combination With Cyclophosphamide Or Gemcitabine For Children And Adolescents With Refractory Or Recurrent Group 3/Group 4 Or Shh Medulloblastoma Brain Tumors
Protocol ID SJ ELiOT
Disease (Sub Disease) Brain and Spinal Tumours (Medulloblastoma/ PNET)
Diagnosis Stage Relapse/ refractory
Location NSW / QLD / VIC / WA
Sponsor Australian and New Zealand Children's Haematology Oncology Group/ St. Jude Children's Research Hospital
Collaborators Eli Lilly and Company
Links https://clinicaltrials.gov/ct2/show/NCT04023669
Trial Status Open
Trial Open Date 02/10/2019
Sites Perth Children's Hospital / Queensland Children's Hospital / Sydney Children's Hospital / Royal Children's Hospital
Study Type Treatment
Phase Phase 1
Age Eligibility 1 year to 25 years
International registry ID's NCT04023669